Objective This study was to investigate the efficacy and safety of gefitinib plus anlotinib for
patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line …

Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …

This study aimed to perform a meta-analysis comparing the efficacy and safety of gefitinib in
combination with chemotherapy versus gefitinib alone in patients with advanced Non-Small …

Purpose To compare gefitinib with placebo in chemotherapy naïve patients with advanced
non–small-cell lung cancer (NSCLC) and poor performance status. Patients and Methods …

9030 Background: Currently, EGFR-TKIs are widely accepted as the standard treatment for
EGFR-mutant advanced non-small-cell lung cancer (NSCLC); however, acquired resistance …

Background Acquired resistance development is a major challenge in the epidermal growth
factor receptor‐tyrosine kinase inhibitor (EGFR–TKI) treatment of non–small cell lung cancer …

Background There are currently no methods for the treatment of reversible drug-resistant
EGFR-TKI lung cancer in the clinical setting, and thus, the patients finally return to the …

Purpose Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …

Purpose To evaluate the effectiveness and safety of gefitinib retreatment beyond disease
progression in patients with advanced non-small cell lung cancer (NSCLC) with sensitive …

TPS9131 Background: Preclinical and clinical evidence has demonstrated that the dual
blockade of the EGFR and VEGF pathways is a viable strategy in the EGFR-mutated …